Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-us...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leukemia
Главные авторы: Vannucchi, Alessandro M., Sordi, Benedetta, Morettini, Alessandro, Nozzoli, Carlo, Poggesi, Loredana, Pieralli, Filippo, Bartoloni, Alessandro, Atanasio, Alessandro, Miselli, Filippo, Paoli, Chiara, Loscocco, Giuseppe G., Fanelli, Andrea, Para, Ombretta, Berni, Andrea, Tassinari, Irene, Zammarchi, Lorenzo, Maggi, Laura, Mazzoni, Alessio, Scotti, Valentina, Falchetti, Giorgia, Malandrino, Danilo, Luise, Fabio, Millotti, Giovanni, Bencini, Sara, Capone, Manuela, Piccinni, Marie Pierre, Annunziato, Francesco, Guglielmelli, Paola
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437386/
https://ncbi.nlm.nih.gov/pubmed/32814839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01018-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы